Axel S. Merseburger – författare

Bladder cancer is a common cancer of the urinary tract. It is the fourth leading cause of cancer-related death among men and the seventh among women. Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis, frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments and poor prognosis of patients with tumors that invade the bladder muscle and beyond. Due to these factors it has been said that the cost per patient of bladder cancer, from diagnosis to death is the highest of all cancers. In addition to it being a significant health problem, bladder cancer is an interesting cancer to study in many ways than one. For example, Environmental factors such as cigarette smoking and other carcinogens play a major role in the development of transitional carcinoma of the bladder, whereas, schitosomasis, a protozoan infection results in squamous cell carcinoma of the bladder. Different molecular pathways with distinct molecular signatures appear to be involved in the development of low-grade versus high-grade bladder tumors. Currently being monitored by an invasive endoscopic procedure, cystectomy, with urine cytology as an adjunct, bladder cancer is at the forefront of developing cancer biomarkers for non-invasive detection. Due to the differences in the invasive and metastatic potential of bladder tumors, treatment options differ depending upon tumor grade and stage. New advances are being made in treatment options to improve the outcome and quality of life for patients with bladder cancer. Similarly, new molecular nomograms are being discovered to predict treatment outcome so that individualized treatment options can be offered to patients.

Bladder cancer is a common cancer of the urinary tract. It is the fourth leading cause of cancer-related death among men and the seventh among women. Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis, frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments and poor prognosis of patients with tumors that invade the bladder muscle and beyond. Due to these factors it has been said that the cost per patient of bladder cancer, from diagnosis to death is the highest of all cancers. In addition to it being a significant health problem, bladder cancer is an interesting cancer to study in many ways than one. For example, Environmental factors such as cigarette smoking and other carcinogens play a major role in the development of transitional carcinoma of the bladder, whereas, schitosomasis, a protozoan infection results in squamous cell carcinoma of the bladder. Different molecular pathways with distinct molecular signatures appear to be involved in the development of low-grade versus high-grade bladder tumors. Currently being monitored by an invasive endoscopic procedure, cystectomy, with urine cytology as an adjunct, bladder cancer is at the forefront of developing cancer biomarkers for non-invasive detection. Due to the differences in the invasive and metastatic potential of bladder tumors, treatment options differ depending upon tumor grade and stage. New advances are being made in treatment options to improve the outcome and quality of life for patients with bladder cancer. Similarly, new molecular nomograms are being discovered to predict treatment outcome so that individualized treatment options can be offered to patients.

This comprehensive and timely textbook covers all aspects of the evidence-based management of genitourinary cancers and explains the fundamental principles underlying the available diagnostic and treatment approaches, including chemotherapy, radiotherapy, immunotherapy, and surgery.

Urology at a Glance is a concise, practical guide to diagnostic and therapeutic decision making. The book is divided into two parts. The first focuses on the pathway from symptom to diagnosis and covers the full range of symptoms commonly encountered by the urologist. Any particular symptom can be located within a matter of seconds and in each case differential diagnosis is explained with the aid of a flow chart. The second part of the book is devoted to the pathway from diagnosis to therapy, with each short chapter devoted to a specific diagnosis. Basic information is provided on the disease in question, along with an outline of state of the art treatment options and possible complications. Again, flow charts are used to help the reader to reach the correct therapeutic decision in different circumstances. Numerous high-definition photographs and illustrations are also included. This book will be a great asset for urologists and practitioners in related disciplines.

Urologisches Medikamentenwissen kompaktDas Buch mit seinen über 150 Medikamentenprofilen ist das ideale Nachschlagewerk für alle Urologen. Schnell und zuverlässig erhält der Arzt alle wichtigen Informationen zu den praxisrelevanten Arzneimitteln, u.a. Wirkung, Nebenwirkungen, Indikationen, Wechselwirkungen und Dosierung. Zusätzlich werden Besonderheiten, zu berücksichtigende Einflussfaktoren (z.B. das Alter) und Hinweise zu Patienteninformationen gegeben.Knapp und handlich bündelt es das pharmakologische Wissen u.a. zur Infektiologie, Inkontinenz, Uroonkologie und möglichen Notfällen urologischer Patienten. Abgestimmt auf das, was jeder Urologe wissen muss.